Mammalian target of rapamycin (mTOR) inhibition with rapamycin improves cardiac function in type 2 diabetic mice : Potential role of attenuated oxidative stress and altered contractile protein expression

Journal of Biological Chemistry

Volumn 289, Issue 7, 2014, Pages 4145-4160

  Das, Anindita ^a   Durrant, David ^a   Koka, Saisudha ^a   Salloum, Fadi N ^a   Xi, Lei ^a   Kukreja, Rakesh C ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANTS; CARDIOVASCULAR DISEASE; DIABETES; MTOR; OXIDATIVE STRESS; PROTEOMICS;

ANIMALS; ANTI-BACTERIAL AGENTS; CONTRACTILE PROTEINS; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION REGULATION; GLUCOSE; MALE; MICE; MICE, MUTANT STRAINS; MYOCARDIAL CONTRACTION; MYOCARDIUM; OXIDATIVE STRESS; PROTEOMICS; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84894143655     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.521062     Document Type: Article

References (74)

1. Plutzky, J. (2011) Macrovascular effects and safety issues of therapies for type 2 diabetes 2. Am. J. Cardiol. 108, 25B-32B
2. Adameova, A., and Dhalla, N. S. (2014) Role of microangiopathy in diabetic cardiomyopathy. Heart Fail. Rev. 19, 25-33
3. Chong, Z. Z., and Maiese, K. (2012) Mammalian target of rapamycin signaling in diabetic cardiovascular disease. Cardiovasc. Diabetol. 11, 45
4. Ernande, L., and Derumeaux, G. (2012) Diabetic cardiomyopathy. Myth or reality? Arch. Cardiovasc. Dis. 105, 218-225
5. Yang, H., Jin, X., Kei Lam, C. W., and Yan, S. K. (2011) Oxidative stress and diabetes mellitus. Clin. Chem. Lab Med. 49, 1773-1782
6. Meric-Bernstam, F., and Gonzalez-Angulo, A. M. (2009) Targeting the mTOR signaling network for cancer therapy. J. Clin. Oncol. 27, 2278-2287
7. Martin, D. E., and Hall, M. N. (2005) The expanding TOR signaling network. Curr. Opin. Cell Biol. 17, 158-166
8. Hara, K., Maruki, Y., Long, X., Yoshino, K., Oshiro, N., Hidayat, S., Tokunaga, C., Avruch, J., and Yonezawa, K. (2002) Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110, 177-189
9. Sarbassov, D. D., Guertin, D. A., Ali, S. M., and Sabatini, D. M. (2005) Phosphorylation and regulation of Akt/PKB by the Rictor-mTOR complex. Science 307, 1098-1101
10. Khan, S., Salloum, F., Das, A., Xi, L., Vetrovec, G. W., and Kukreja, R. C. (2006) Rapamycin confers preconditioning-like protection against ischemia-reperfusion injury in isolated mouse heart and cardiomyocytes. J. Mol. Cell Cardiol. 41, 256-264
11. Das, A., Salloum, F. N., Durrant, D., Ockaili, R., and Kukreja, R. C. (2012) Rapamycin protects against myocardial ischemia-reperfusion injury through JAK2-STAT3 signaling pathway. J. Mol. Cell Cardiol. 53, 858-869
12. Gao, X. M., Wong, G., Wang, B., Kiriazis, H., Moore, X. L., Su, Y. D., Dart, A., and Du, X. J. (2006) Inhibition of mTOR reduces chronic pressureoverload cardiac hypertrophy and fibrosis. J. Hypertens. 24, 1663-1670
13. Völkers, M., Konstandin, M. H., Doroudgar, S., Toko, H., Quijada, P., Din, S., Joyo, A., Ornelas, L., Samse, K., Thuerauf, D. J., Gude, N., Glembotski, C. C., and Sussman, M. A. (2013) Mechanistic target of rapamycin complex 2 protects the heart from ischemic damage. Circulation 128, 2132-2144
14. Khamzina, L., Veilleux, A., Bergeron, S., and Marette, A. (2005) Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats. Possible involvement in obesity-linked insulin resistance. Endocrinology 146, 1473-1481
15. Drake, J. C., Alway, S. E., Hollander, J. M., and Williamson, D. L. (2010) AICAR treatment for 14 days normalizes obesity-induced dysregulation of TORC1 signaling and translational capacity in fasted skeletal muscle. Am. J. Physiol. Regul. Integr. Comp. Physiol. 299, R1546-R1554
16. Ranieri, S. C., Fusco, S., Panieri, E., Labate, V., Mele, M., Tesori, V., Ferrara, A. M., Maulucci, G., De Spirito, M., Martorana, G. E., Galeotti, T., and Pani, G. (2010) Mammalian life-span determinant p66shcA mediates obesity-induced insulin resistance. Proc. Natl. Acad. Sci. U.S.A. 107, 13420-13425
17. Um, S. H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P. R., Kozma, S. C., Auwerx, J., and Thomas, G. (2004) Absence of S6K1 protects against age-and diet-induced obesity while enhancing insulin sensitivity. Nature 431, 200-205
18. Sung, M. M., Koonen, D. P., Soltys, C. L., Jacobs, R. L., Febbraio, M., and Dyck, J. R. (2011) Increased CD36 expression in middle-aged mice contributes to obesity-related cardiac hypertrophy in the absence of cardiac dysfunction. J. Mol. Med. 89, 459-469
19. Turdi, S., Kandadi, M. R., Zhao, J., Huff, A. F., Du, M., and Ren, J. (2011) Deficiency in AMP-activated protein kinase exaggerates high fat dietinduced cardiac hypertrophy and contractile dysfunction. J. Mol. Cell Cardiol. 50, 712-722
20. Inoki, K., Mori, H., Wang, J., Suzuki, T., Hong, S., Yoshida, S., Blattner, S. M., Ikenoue, T., Rüegg, M. A., Hall, M. N., Kwiatkowski, D. J., Rastaldi, M. P., Huber, T. B., Kretzler, M., Holzman, L. B., Wiggins, R. C., and Guan, K. L. (2011) mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J. Clin. Invest. 121, 2181-2196
21. Mori, H., Inoki, K., Masutani, K., Wakabayashi, Y., Komai, K., Nakagawa, R., Guan, K. L., and Yoshimura, A. (2009) The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential. Biochem. Biophys. Res. Commun. 384, 471-475
22. Baumgart, D., Klauss, V., Baer, F., Hartmann, F., Drexler, H., Motz, W., Klues, H., Hofmann, S., Völker, W., Pfannebecker, T., Stoll, H. P., and Nickenig, G. (2007) One-year results of the SCORPIUS study. A German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. J. Am. Coll. Cardiol. 50, 1627-1634
23. de Waha, A., Dibra, A., Kufner, S., Baumgart, D., Sabate, M., Maresta, A., Schömig, A., and Kastrati, A. (2011) Long-term outcome after sirolimuseluting stents versus bare metal stents in patients with diabetes mellitus.A patient-level meta-analysis of randomized trials. Clin. Res. Cardiol. 100, 561-570
24. Koka, S., Xi, L., and Kukreja, R. C. (2012) Chronic treatment with long acting phosphodiesterase-5 inhibitor tadalafil alters proteomic changes associated with cytoskeletal rearrangement and redox regulation in Type 2 diabetic hearts. Basic Res. Cardiol. 107, 249
25. Xi, L., Zhu, S. G., Hobbs, D. C., and Kukreja, R. C. (2011) Identification of protein targets underlying dietary nitrate-induced protection against doxorubicin cardiotoxicity. J. Cell Mol. Med. 15, 2512-2524
26. Salloum, F. N., Abbate, A., Das, A., Houser, J. E., Mudrick, C. A., Qureshi, I. Z., Hoke, N. N., Roy, S. K., Brown, W. R., Prabhakar, S., and Kukreja, R. C. (2008) Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. Am. J. Physiol. Heart Circ. Physiol. 294, H1398-H1406
27. Lamming, D. W., Ye, L., Katajisto, P., Goncalves, M. D., Saitoh, M., Stevens, D. M., Davis, J. G., Salmon, A. B., Richardson, A., Ahima, R. S., Guertin, D. A., Sabatini, D. M., and Baur, J. A. (2012) Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 335, 1638-1643
28. Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J. H., Hsu, P. P., Bagley, A. F., Markhard, A. L., and Sabatini, D. M. (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22, 159-168
29. Mellor, K. M., Bell, J. R., Young, M. J., Ritchie, R. H., and Delbridge, L. M. (2011) Myocardial autophagy activation and suppressed survival signaling is associated with insulin resistance in fructose-fed mice. J. Mol. Cell Cardiol. 50, 1035-1043
30. Mellor, K. M., Reichelt, M. E., and Delbridge, L. M. (2011) Autophagy anomalies in the diabetic myocardium. Autophagy. 7, 1263-1267
31. Dutta, D., Xu, J., Kim, J. S., Dunn, W. A., Jr., and Leeuwenburgh, C. (2013) Upregulated autophagy protects cardiomyocytes from oxidative stressinduced toxicity. Autophagy 9, 328-344
32. French, C. J., Tarikuz Zaman,A., McElroy-Yaggy, K. L., Neimane, D. K., and Sobel, B. E. (2011) Absence of altered autophagy after myocardial ischemia in diabetic compared with nondiabetic mice. Coron. Artery Dis. 22, 479-483
33. Mellor, K. M., Bell, J. R., Ritchie, R. H., and Delbridge, L. M. (2013) Myocardial insulin resistance, metabolic stress and autophagy in diabetes. Clin. Exp. Pharmacol. Physiol. 40, 56-61
34. Thoreen, C. C., and Sabatini, D. M. (2009) Rapamycin inhibits mTORC1, but not completely. Autophagy 5, 725-726
35. Thoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., Sabatini, D. M., and Gray, N. S. (2009) An ATPcompetitive mammalian target of rapamycin inhibitor reveals rapamycinresistant functions of mTORC1. J. Biol. Chem. 284, 8023-8032
36. Thoreen, C. C., Chantranupong, L., Keys, H. R., Wang, T., Gray, N. S., and Sabatini, D. M. (2012) A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 485, 109-113
37. Jweied, E. E., McKinney, R. D., Walker, L. A., Brodsky, I., Geha, A. S., Massad, M. G., Buttrick, P. M., and de Tombe, P. P. (2005) Depressed cardiac myofilament function in human diabetes mellitus. Am. J. Physiol. Heart Circ. Physiol. 289, H2478-H2483
38. Pereira, L., Matthes, J., Schuster, I., Valdivia, H. H., Herzig, S., Richard, S., and Gómez, A. M. (2006) Mechanisms of [Ca2+]i transient decrease in cardiomyopathy of db/db type 2 diabetic mice. Diabetes 55, 608-615
39. Dillmann, W. H. (1980) Diabetes mellitus induces changes in cardiac myosin of the rat. Diabetes 29, 579-582
40. Dillmann, W. H. (1986) Diabetes mellitus and hypothyroidism induce changes in myosin isoenzyme distribution in the rat heart-do alterations in fuel flux mediate these changes? Adv. Exp. Med. Biol. 194, 469-479
41. Essop, M. F., Chan, W. A., and Hattingh, S. (2011) Proteomic analysis of mitochondrial proteins in a mouse model of type 2 diabetes. Cardiovasc. J. Afr. 22, 175-178
42. Howarth, F. C., Qureshi, M. A., Hassan, Z., Al Kury, L. T., Isaev, D., Parekh, K., Yammahi, S. R., Oz, M., Adrian, T. E., and Adeghate, E. (2011) Changing pattern of gene expression is associated with ventricular myocyte dysfunction and altered mechanisms of Ca2+ signalling in young type 2 Zucker diabetic fatty rat heart. Exp. Physiol. 96, 325-337
43. Pohlmann, L., Kröger, I., Vignier, N., Schlossarek, S., Krämer, E., Coirault, C., Sultan, K. R., El-Armouche, A., Winegrad, S., Eschenhagen, T., and Carrier, L. (2007) Cardiac myosin-binding protein C is required for complete relaxation in intact myocytes. Circ. Res. 101, 928-938
44. Vignier, N., Schlossarek, S., Fraysse, B., Mearini, G., Krämer, E., Pointu, H., Mougenot, N., Guiard, J., Reimer, R., Hohenberg, H., Schwartz, K., Vernet, M., Eschenhagen, T., and Carrier, L. (2009) Nonsense-mediated mRNA decay and ubiquitin-proteasome system regulate cardiac myosin-binding protein C mutant levels in cardiomyopathic mice. Circ. Res. 105, 239-248
45. Brickson, S., Fitzsimons, D. P., Pereira, L., Hacker, T., Valdivia, H., and Moss, R. L. (2007) In vivo left ventricular functional capacity is compromised in cMyBP-C null mice. Am. J. Physiol. Heart Circ. Physiol. 292, H1747-H1754
46. Stöhr, A., Friedrich, F. W., Flenner, F., Geertz, B., Eder, A., Schaaf, S., Hirt, M. N., Uebeler, J., Schlossarek, S., Carrier, L., Hansen, A., and Eschenhagen, T. (2013) Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice. J. Mol. Cell Cardiol. 63, 189-198
47. Maiellaro-Rafferty, K., Wansapura, J. P., Mendsaikhan, U., Osinska, H., James, J. F., Taylor, M. D., Robbins, J., Kranias, E. G., Towbin, J. A., and Purevjav, E. (2013) Altered regional cardiac wall mechanics are associated with differential cardiomyocyte calcium handling due to nebulette mutations in preclinical inherited dilated cardiomyopathy. J. Mol. Cell Cardiol. 60, 151-160
48. Purevjav, E., Varela, J., Morgado, M., Kearney, D. L., Li, H., Taylor, M. D., Arimura, T., Moncman, C. L., McKenna, W., Murphy, R. T., Labeit, S., Vatta, M., Bowles, N. E., Kimura, A., Boriek, A. M., and Towbin, J. A. (2010) Nebulette mutations are associated with dilated cardiomyopathy and endocardial fibroelastosis. J. Am. Coll. Cardiol. 56, 1493-1502
49. Wang, B. T., Ducker, G. S., Barczak, A. J., Barbeau, R., Erle, D. J., and Shokat, K. M. (2011) The mammalian target of rapamycin regulates cholesterol biosynthetic gene expression and exhibits a rapamycin-resistant transcriptional profile. Proc. Natl. Acad. Sci. U.S.A. 108, 15201-15206
50. Boudina, S., and Abel, E. D. (2007) Diabetic cardiomyopathy revisited. Circulation 115, 3213-3223
51. Cai, L., Wang, Y., Zhou, G., Chen, T., Song, Y., Li, X., and Kang, Y. J. (2006) Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. J. Am. Coll. Cardiol. 48, 1688-1697
52. Matsushima, S., Kinugawa, S., Ide, T., Matsusaka, H., Inoue, N., Ohta, Y., Yokota, T., Sunagawa, K., and Tsutsui, H. (2006) Overexpression of glutathione peroxidase attenuates myocardial remodeling and preserves diastolic function in diabetic heart. Am. J. Physiol. Heart Circ. Physiol. 291, H2237-H2245
53. Matsushima, S., Ide, T., Yamato, M., Matsusaka, H., Hattori, F., Ikeuchi, M., Kubota, T., Sunagawa, K., Hasegawa, Y., Kurihara, T., Oikawa, S., Kinugawa, S., and Tsutsui, H. (2006) Overexpression of mitochondrial peroxiredoxin-3 prevents left ventricular remodeling and failure after myocardial infarction in mice. Circulation 113, 1779-1786
54. Shen, X., Zheng, S., Metreveli, N. S., and Epstein, P. N. (2006) Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes 55, 798-805
55. Jiang, J., Jiang, J., Zuo, Y., and Gu, Z. (2013) Rapamycin protects the mitochondria against oxidative stress and apoptosis in a rat model of Parkinson's disease. Int. J. Mol. Med. 31, 825-832
56. Rajapakse, A. G., Yepuri, G., Carvas, J. M., Stein, S., Matter, C. M., Scerri, I., Ruffieux, J., Montani, J. P., Ming, X. F., and Yang, Z. (2011) Hyperactive S6K1 mediates oxidative stress and endothelial dysfunction in aging. Inhibition by resveratrol. PLoS One 6, e19237
57. Gao, G., Li, J. J., Li, Y., Li, D., Wang, Y., Wang, L., Tang, X. D., Walsh, M. P., Gui, Y., and Zheng, X. L. (2011) Rapamycin inhibits hydrogen peroxideinduced loss of vascular contractility. Am. J. Physiol. Heart Circ. Physiol. 300, H1583-H1594
58. Shin, Y. J., Cho, D. Y., Chung, T. Y., Han, S. B., Hyon, J. Y., and Wee, W. R. (2011) Rapamycin reduces reactive oxygen species in cultured human corneal endothelial cells. Curr. Eye Res. 36, 1116-1122
59. Fujii, J., and Ikeda, Y. (2002) Advances in our understanding of peroxiredoxin, a multifunctional, mammalian redox protein. Redox. Rep. 7, 123-130
60. Banmeyer, I., Marchand, C., Clippe, A., and Knoops, B. (2005) Human mitochondrial peroxiredoxin 5 protects from mitochondrial DNA damages induced by hydrogen peroxide. FEBS Lett. 579, 2327-2333
61. Pham, C. G., Bubici, C., Zazzeroni, F., Papa, S., Jones, J., Alvarez, K., Jayawardena, S., De Smaele, E., Cong, R., Beaumont, C., Torti, F. M., Torti, S. V., and Franzoso, G. (2004) Ferritin heavy chain upregulation by NF-B inhibits TNF-induced apoptosis by suppressing reactive oxygen species. Cell 119, 529-542
62. Kukreja, R. C., and Hess, M. L. (1992) The oxygen free radical system. From equations through membrane-protein interactions to cardiovascular injury and protection. Cardiovasc. Res. 26, 641-655
63. Omiya, S., Hikoso, S., Imanishi, Y., Saito, A., Yamaguchi, O., Takeda, T., Mizote, I., Oka, T., Taneike, M., Nakano, Y., Matsumura, Y., Nishida, K., Sawa, Y., Hori, M., and Otsu, K. (2009) Downregulation of ferritin heavy chain increases labile iron pool, oxidative stress and cell death in cardiomyocytes. J. Mol. Cell Cardiol. 46, 59-66
64. Torti, F. M., and Torti, S. V. (2002) Regulation of ferritin genes and protein. Blood 99, 3505-3516
65. Chambers, K. T., Leone, T. C., Sambandam, N., Kovacs, A., Wagg, C. S., Lopaschuk, G. D., Finck, B. N., and Kelly, D. P. (2011) Chronic inhibition of pyruvate dehydrogenase in heart triggers an adaptive metabolic response. J. Biol. Chem. 286, 11155-11162
66. Schroeder, M. A., Ali, M. A., Hulikova, A., Supuran, C. T., Clarke, K., Vaughan-Jones, R. D., Tyler, D. J., and Swietach, P. (2013) Extramitochondrial domain rich in carbonic anhydrase activity improves myocardial energetics. Proc. Natl. Acad. Sci. U.S.A. 110, E958-E967
67. Sterling, D., Reithmeier, R. A., and Casey, J. R. (2001) A transport metabolon. Functional interaction of carbonic anhydrase II and chloride/bicarbonate exchangers. J. Biol. Chem. 276, 47886-47894
68. Lai, L. W., Chan, D. M., Erickson, R. P., Hsu, S. J., and Lien, Y. H. (1998) Correction of renal tubular acidosis in carbonic anhydrase II-deficient mice with gene therapy. J. Clin. Invest. 101, 1320-1325
69. Sly, W. S., Hewett-Emmett, D., Whyte, M. P., Yu, Y. S., and Tashian, R. E. (1983) Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc. Natl. Acad. Sci. U.S.A. 80, 2752-2756
70. Alvarez, B. V., Johnson, D. E., Sowah, D., Soliman, D., Light, P. E., Xia, Y., Karmazyn, M., and Casey, J. R. (2007) Carbonic anhydrase inhibition prevents and reverts cardiomyocyte hypertrophy. J. Physiol. 579, 127-145
71. Brown, B. F., Quon, A., Dyck, J. R., and Casey, J. R. (2012) Carbonic anhydrase II promotes cardiomyocyte hypertrophy. Can. J. Physiol. Pharmacol. 90, 1599-1610
72. Robishaw, J. D., Berkich, D., and Neely, J. R. (1982) Rate-limiting step and control of coenzyme A synthesis in cardiac muscle. J. Biol. Chem. 257, 10967-10972
73. Reibel, D. K., Wyse, B. W., Berkich, D. A., and Neely, J. R. (1981) Regulation of coenzyme A synthesis in heart muscle. Effects of diabetes and fasting. Am. J. Physiol. 240, H606-H611
74. Deepa, S. S., Walsh, M. E., Hamilton, R. T., Pulliam, D., Shi, Y., Hill, S., Li, Y., and Remmen, H. V. (2013) Rapamycin modulates markers of mitochondrial biogenesis and fatty acid oxidation in the adipose tissue of db/db mice. J. Biochem. Pharmacol. Res. 1, 114-123